Dapagliflozin Dosing and Safety Considerations

Introduction to Dapagliflozin

• The Kidney International guidelines recommend that dapagliflozin is not used for glycemic control when eGFR <45 mL/min/1.73 m² 1, 2
• The American College of Cardiology recommends a fixed dose of 10 mg orally once daily for heart failure (with or without reduced ejection fraction) 3

Renal Dosing Considerations

• For patients with eGFR ≥45 mL/min/1.73 m², no dose adjustment is required for glycemic control 1
• For patients with eGFR <45 mL/min/1.73 m², dapagliflozin is not recommended for glycemic control (likely ineffective) 4
• For patients with eGFR <25 mL/min/1.73 m², dapagliflozin is not recommended for initiation 1
• If eGFR falls below 25 mL/min/1.73 m² during treatment, 10 mg daily may be continued 5

Special Considerations

• The American College of Cardiology recommends withholding dapagliflozin for at least 3 days prior to major surgery or procedures requiring prolonged fasting 6
• Genital mycotic infections, urinary tract infections, volume depletion, and euglycemic diabetic ketoacidosis are potential adverse effects to monitor 1, 6

Monitoring and Assessment

• The Kidney International guidelines recommend assessing renal function prior to initiation and periodically thereafter 5
• Volume status should be assessed before starting dapagliflozin, and volume depletion should be corrected if present 5
• Glucose-lowering efficacy decreases with declining renal function, but cardiovascular and renal benefits are preserved at lower eGFR levels 1, 2

Dapagliflozina en Insuficiencia Renal

Recomendaciones de dosificación y eficacia

• En pacientes con TFGe <45 mL/min/1,73 m², la dapagliflozina no es recomendada para control glucémico ya que probablemente sea ineficaz debido a su mecanismo de acción, según el Mayo Clinic Proceedings 7
• El estudio DAPA-CKD demostró que en pacientes con enfermedad renal crónica con TFGe entre 25-75 mL/min/1,73 m², la dapagliflozina redujo significativamente el riesgo de un deterioro sostenido de la TFGe, enfermedad renal terminal o muerte por causas renales o cardiovasculares, independientemente de la presencia de diabetes 8

Beneficios cardiovasculares y renales

• La eficacia hipoglucemiante disminuye con el deterioro de la función renal, pero los beneficios cardiovasculares y renales se mantienen en niveles más bajos de TFGe, según el Mayo Clinic Proceedings 7
• En pacientes con diabetes tipo 2 y enfermedad renal diabética, los inhibidores SGLT2 han demostrado reducir la progresión de la enfermedad renal y eventos cardiovasculares incluso con TFGe <30 mL/min/1,73 m², según Diabetes Care 9, 10

Renal Indications for Dapagliflozine Therapy

Benefits of Dapagliflozine in Renal Disease

• The American Diabetes Association recommends dapagliflozine for patients with chronic kidney disease (CKD) and an estimated glomerular filtration rate (eGFR) between 25-75 mL/min/1.73 m², with albuminuria (UACR 200-5000 mg/g), to reduce the risk of kidney disease progression, end-stage renal disease, and cardiovascular mortality 11
• The DAPA-CKD study showed that dapagliflozine reduces the risk of the composite outcome of sustained decline in eGFR of at least 50%, end-stage renal disease, or renal or cardiovascular death by 39% (HR 0.61 [95% CI 0.51-0.72]) 11
• Dapagliflozine reduces the risk of the composite renal outcome (sustained decline in eGFR of at least 50%, end-stage renal disease, or renal death) by 44% (HR 0.56 [95% CI 0.45-0.68]) 11
• Dapagliflozine slows the rate of eGFR decline 12, 13
• Dapagliflozine reduces the risk of cardiovascular death or hospitalization for heart failure by 29% (HR 0.71 [95% CI 0.55-0.92]) 11, 14

Dapagliflozin eGFR Cut-Off for Initiation in Patients with Impaired Renal Function

eGFR Thresholds for Dapagliflozin Initiation

• Dapagliflozin can be initiated at 10 mg daily in patients with eGFR ≥45 mL/min/1.73 m² for glycemic control 15
• Dapagliflozin is not recommended for initiation when eGFR <45 mL/min/1.73 m² if the primary goal is glycemic control, as glucose-lowering efficacy is significantly reduced at lower eGFR levels 15

Cardiovascular and Renal Benefits

• The DAPA-CKD trial demonstrated significant benefits in patients with eGFR between 25-75 mL/min/1.73 m² 16, 17
• Dapagliflozin reduced the primary composite endpoint (≥50% sustained decline in eGFR, ESKD, or renal/CV death) by 39% (HR 0.61 [95% CI 0.51-0.72]) 16

Clinical Practice Algorithm

• For cardiovascular/renal protection, the American College of Cardiology and other guideline societies may recommend using dapagliflozin if eGFR ≥25 mL/min/1.73 m², as supported by the DAPA-CKD trial 16, 17
• Consider GLP-1 receptor agonists as preferred agents for patients with eGFR <25 mL/min/1.73 m², as suggested by the Mayo Clinic Proceedings 18, 15

Dapagliflozin Use in Patients with Advanced Chronic Kidney Disease

Rationale for Not Using Dapagliflozin for Glycemic Control

• Dapagliflozin is contraindicated for glycemic control when eGFR is <30 mL/min/1.73 m² according to dosing guidelines 19
• At an eGFR of 20 mL/min/1.73 m², the drug's mechanism of action (inhibition of renal sodium-glucose cotransporter-2) is significantly impaired, resulting in minimal glycemic benefit 20

Alternative Uses of Dapagliflozin in Advanced CKD

• Dapagliflozin can be considered for cardiovascular and renal protection in patients with eGFR ≥20 mL/min/1.73 m² regardless of glycemic control needs 20, 21

Alternative Medications for Glycemic Control in Advanced CKD

• GLP-1 receptor agonists like liraglutide or semaglutide, which have demonstrated cardiovascular benefits and can be used with eGFR >30 mL/min/1.73 m² 22, 20
• Insulin therapy, which remains effective regardless of kidney function and can be dose-adjusted based on clinical response 20
• DPP-4 inhibitors, which may require dose adjustment but can be used in advanced CKD 20

Clinical Decision Algorithm

• For patients with eGFR of 20 mL/min/1.73 m², do not use dapagliflozin for glycemic control, but consider it for cardiovascular/renal protection 19, 20
• For glycemic control in these patients, use insulin as primary therapy if needed, and consider GLP-1 receptor agonists if eGFR improves to >30 mL/min/1.73 m² 20, 22, 20

Utilisation de la Dapagliflozine dans la Maladie Rénale Chronique

Recommandations Basées sur le Niveau d'Albuminurie

• La dapagliflozine est fortement recommandée chez les adultes présentant une maladie rénale chronique avec un rapport albumine/créatinine urinaire (UACR) ≥30 mg/g, à condition que le DFGe soit ≥25 mL/min/1,73 m², selon les recommandations de la société de diabétologie, basées sur des preuves de niveau 1A 23, 24, 25
• Les inhibiteurs SGLT2 comme la dapagliflozine sont recommandés comme traitement de première ligne pour la protection rénale et cardiovasculaire chez les patients avec DFGe ≥20 mL/min/1,73 m² et UACR ≥200 mg/g, avec une recommandation forte (1A) de l'American Journal of Kidney Diseases 25
• L'essai DAPA-CKD a démontré une réduction de 39% du risque de progression de la maladie rénale chez les patients avec UACR médian de 949 mg/g, avec une force de preuve élevée 23, 24
• Les bénéfices cardiovasculaires incluent une réduction de 29% du risque de décès cardiovasculaire ou d'hospitalisation pour insuffisance cardiaque, selon les données de l'essai DAPA-CKD 24

Seuils de DFGe pour l'Initiation et la Continuation

• L'initiation de la dapagliflozine est recommandée si DFGe ≥25 mL/min/1,73 m² avec albuminurie, selon les recommandations de la société de diabétologie, basées sur des preuves de niveau 1A 23, 25
• La dapagliflozine peut être continuée même si le DFGe descend en dessous de 25 mL/min/1,73 m² chez les patients déjà sous traitement, jusqu'à l'initiation de la dialyse, avec une recommandation de l'American Journal of Kidney Diseases 25

Considérations Importantes et Précautions

• Une baisse réversible du DFGe de 3-5 mL/min/1,73 m² est attendue dans les 4 premières semaines, suivie d'une stabilisation, selon les données de l'American Journal of Kidney Diseases 25
• La dapagliflozine réduit le risque d'hyperkaliémie et peut faciliter l'utilisation d'antagonistes des récepteurs minéralocorticoïdes, avec une force de preuve élevée 25
• Les patients doivent être éduqués sur les symptômes d'infections génitales/urinaires et sur la manière de les prévenir, selon les recommandations de l'American Journal of Kidney Diseases 25

Dapagliflozin Use in Patients with Raised Creatinine

Initiation and Monitoring

• The American College of Cardiology recommends initiating dapagliflozin 10 mg daily if eGFR ≥25 mL/min/1.73 m² for heart failure or chronic kidney disease indications 26
• The American Journal of Kidney Diseases suggests that an initial eGFR dip of 3-5 mL/min/1.73 m² typically occurs within the first 1-4 weeks of dapagliflozin initiation, which is transient and reversible 27
• Check eGFR and creatinine within 1-2 weeks after initiation, and evaluate volume status before starting and monitor closely for intravascular volume contraction 26
• If eGFR decreases >30% from baseline AND there are signs of hypovolemia, reduce diuretic doses first before considering dapagliflozin adjustment 26

Renal Protection

• Dapagliflozin reduces the risk of abrupt declines in kidney function (doubling of creatinine: HR 0.68, 95% CI 0.49-0.94), according to the American Journal of Kidney Diseases 27
• Patients experiencing an acute eGFR reduction >10% at 2 weeks actually had better long-term renal outcomes with slower eGFR decline (-1.58 vs -2.44 ml/min/1.73 m²/year) compared to those without an initial dip 27

Dapagliflozin Contraindications and Precautions

Critical Warnings and Precautions

• Withhold dapagliflozin at least 3 days before major surgery or procedures with prolonged fasting to prevent postoperative ketoacidosis, as recommended by the American Diabetes Association, with a strength of evidence based on clinical trials 28
• Use caution in patients with renal impairment, low systolic blood pressure, those on diuretics, or elderly patients due to risk of intravascular volume contraction, as suggested by the American College of Cardiology, with moderate-quality evidence 28, 29, and 30
• Increased risk of genital mycotic infections; avoid use in high-risk individuals, according to the American Diabetes Association, with a strength of evidence based on clinical trials 28
• Rare but serious: necrotizing fasciitis of the perineum (Fournier gangrene) requires prompt treatment if suspected, as recommended by the American Diabetes Association, with a strength of evidence based on clinical trials 28

Dapagliflozin Sick Day Management Rules

Introduction to Sick Day Management

• The Kidney International recommends holding dapagliflozin during acute illness to prevent diabetic ketoacidosis and volume depletion 31

When to Withhold Dapagliflozin

• Temporarily discontinue dapagliflozin during any acute illness, particularly when patients experience reduced food and fluid intake 32
• The Kidney International suggests withholding dapagliflozin during fever, vomiting, or diarrhea 31
• The Mayo Clinic Proceedings recommends discontinuing dapagliflozin during any intercurrent illness requiring hospitalization 32

Critical Monitoring During Illness

• Monitor for diabetic ketoacidosis (DKA) even with normal blood glucose levels, as this is a serious risk during illness in patients taking SGLT2 inhibitors, according to the Mayo Clinic Proceedings 32
• Check blood or urine ketones if patients develop malaise, nausea, or vomiting, as recommended by the Mayo Clinic Proceedings 32
• Assess volume status carefully, as the diuretic effect of dapagliflozin combined with illness-related fluid losses significantly increases risk of hypovolemia, according to the Kidney International 31

Patient Education Requirements

• Counsel patients to stop dapagliflozin immediately when they become sick and contact their healthcare provider, as recommended by the Kidney International 31
• Educate patients on specific triggers that necessitate drug discontinuation, including reduced ability to eat or drink normally, according to the Mayo Clinic Proceedings 32
• Instruct patients to seek immediate medical attention if they develop symptoms of DKA or severe genital/urinary infections, as recommended by the Mayo Clinic Proceedings 32

Insulin Management During Sick Days

• Maintain at least low-dose insulin in insulin-requiring individuals even when dapagliflozin is held, as complete insulin cessation increases DKA risk, according to the Kidney International 31
• Do not reduce insulin doses excessively when holding dapagliflozin during illness, as this combination significantly elevates ketoacidosis risk, according to the Mayo Clinic Proceedings 32

When to Restart Dapagliflozin

• Resume dapagliflozin only after patient has recovered from acute illness, as recommended by the Kidney International 31
• Resume dapagliflozin only after normal oral intake is re-established, according to the Mayo Clinic Proceedings 32

Additional Safety Considerations

• Consider proactive dose reduction of concurrent diuretics in patients at high risk for volume depletion before illness occurs, as recommended by the Kidney International 31
• The Kidney International suggests that patients already on diuretic therapy are at higher risk of volume depletion 31

Dapagliflozin Dosing and Clinical Considerations

Introduction to Dapagliflozin Dosing

• The American College of Cardiology recommends dapagliflozin dosing based on the indication and eGFR level, with a dose of 10 mg daily for cardiovascular and renal protection if eGFR ≥25 mL/min/1.73 m² 33
• For glycemic control in type 2 diabetes, dapagliflozin should not be initiated if eGFR <45 mL/min/1.73 m², and the dose should be started at 5 mg once daily if eGFR ≥45 mL/min/1.73 m², with possible increase to 10 mg once daily if additional glycemic control is needed 33

Dosing Algorithm by Indication and eGFR

• For patients with eGFR ≥25 mL/min/1.73 m², a fixed dose of 10 mg once daily is recommended for cardiovascular and renal protection, regardless of diabetes status 33
• For patients with eGFR <25 mL/min/1.73 m², initiation of dapagliflozin is not recommended, but if already on treatment, 10 mg daily may be continued in patients with heart failure or CKD until dialysis is initiated 33

Evidence Supporting Renal and Cardiovascular Benefits

• The DAPA-CKD trial demonstrated that dapagliflozin 10 mg daily reduced the primary composite outcome of sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death by 39% (HR 0.61 [95% CI 0.51-0.72]) in patients with CKD and albuminuria 34, 35
• The renal composite outcome was reduced by 44% (HR 0.56 [95% CI 0.45-0.68]), and cardiovascular death or heart failure hospitalization was reduced by 29% (HR 0.71 [95% CI 0.55-0.92]) in the DAPA-CKD trial 34, 35

Dapagliflozin Dosing in HFrEF with Diabetes and CKD

Introduction to Dapagliflozin Dosing

• The American College of Cardiology recommends initiating dapagliflozin 10 mg once daily for cardiovascular and renal protection in patients with HFrEF and CKD, provided the eGFR is ≥25 mL/min/1.73 m² 36

Dosing Considerations

• For patients with eGFR ≥25 mL/min/1.73 m², the recommended dose of dapagliflozin is 10 mg orally once daily, regardless of diabetes status, for heart failure and CKD indications 36
• Dapagliflozin should not be used for glycemic control if eGFR <45 mL/min/1.73 m², as it is likely ineffective due to its mechanism of action, although the 10 mg dose remains appropriate for cardiovascular and renal protection at eGFR 25-44 mL/min/1.73 m² 36
• If eGFR falls below 25 mL/min/1.73 m² in a patient already on dapagliflozin, continue 10 mg daily until dialysis is required 36

Monitoring and Safety

• Patients on dapagliflozin should be monitored for genital mycotic infections and urinary tract infections, which occur more frequently with SGLT2 inhibitors, and educated about euglycemic diabetic ketoacidosis (DKA), particularly those on insulin 36

Dapagliflozin Dosing in HFrEF with Diabetes and CKD

Introduction to Dapagliflozin Therapy

• The American College of Cardiology recommends dapagliflozin 10 mg daily for patients with HFrEF, diabetes, and CKD, as it reduces cardiovascular death or worsening heart failure by 26% and kidney failure risk by 44%, with benefits consistent across the spectrum of kidney function down to eGFR 25 mL/min/1.73 m² 37, 38

Dosing and Renal Considerations

• For patients with HFrEF and CKD, the American College of Cardiology suggests initiating dapagliflozin 10 mg once daily, with no dose adjustment required for eGFR levels down to 25 mL/min/1.73 m², as the cardiovascular and renal protective benefits are preserved 37, 38
• The American College of Cardiology advises against reducing or discontinuing dapagliflozin solely because eGFR is <45 mL/min/1.73 m², as the cardiovascular and renal protective benefits remain, even if glycemic efficacy is lost 37, 38

Timing and Initiation of Therapy

• The American College of Cardiology recommends initiating dapagliflozin early as part of foundational HFrEF therapy, alongside ACE inhibitors/ARNIs, beta-blockers, and mineralocorticoid receptor antagonists, with the goal of achieving optimal guideline-directed medical therapy within 3-6 months of HF diagnosis 37, 38

Dapagliflozin in Chronic Kidney Disease

Indications and Patient Selection

• The American Diabetes Association recommends dapagliflozin 10 mg once daily for patients with CKD to reduce the risk of kidney failure, cardiovascular death, and heart failure hospitalization, and should be initiated in patients with eGFR ≥20 mL/min/1.73 m² and UACR ≥200 mg/g, regardless of diabetes status 39
• Dapagliflozin provides benefit in patients both with and without type 2 diabetes, with consistent efficacy across both groups, as shown in the DAPA-CKD trial which included 67.5% with diabetes and 32.5% without diabetes 40

Clinical Efficacy

• Dapagliflozin reduced the primary composite endpoint of ≥50% sustained eGFR decline, end-stage kidney disease, or kidney/cardiovascular death by 39% (HR 0.61, 95% CI 0.51-0.72, p<0.001) in the DAPA-CKD trial 40
• The kidney-specific composite of ≥50% sustained eGFR decline, end-stage kidney disease, or renal death was reduced by 44% (HR 0.56, 95% CI 0.45-0.68, p<0.001) in the DAPA-CKD trial 40
• Dapagliflozin reduced cardiovascular death or hospitalization for heart failure by 29% (HR 0.71, 95% CI 0.55-0.92, p=0.009) in the DAPA-CKD trial 40

Dosing and Administration

• The American College of Cardiology recommends a fixed dose of 10 mg orally once daily for cardiovascular and renal protection, regardless of eGFR level (as long as ≥20 mL/min/1.73 m²) 39

Clinical Decision Algorithm

• For patients with CKD and eGFR ≥20 mL/min/1.73 m², the National Kidney Foundation recommends initiating dapagliflozin 10 mg daily for renal and cardiovascular protection if UACR ≥200 mg/g 41, 39

Dapagliflozin Dosage Considerations

Renal Considerations

• The Kidney International guidelines recommend that dapagliflozin should not be initiated for glycemic control if eGFR <45 mL/min/1.73 m², as glucose-lowering efficacy is significantly reduced 42
• For cardiovascular/renal protection, dapagliflozin can be initiated if eGFR ≥25 mL/min/1.73 m², with some guidelines allowing initiation at eGFR ≥20 mL/min/1.73 m² 42, 43
• If eGFR falls below 25 mL/min/1.73 m² during treatment, dapagliflozin 10 mg daily may be continued until dialysis, according to the Kidney International guidelines 42, 43

Safety Precautions

• When switching to dapagliflozin, consider reducing concurrent diuretic doses to prevent excessive volume depletion, as recommended by the Kidney International guidelines 43
• The Kidney International guidelines suggest adjusting sulfonylurea doses as needed based on glucose monitoring when starting dapagliflozin 42
• Patients should be educated to withhold dapagliflozin during acute illness, particularly with reduced oral intake, fever, vomiting, or diarrhea, and maintain at least low-dose insulin in insulin-requiring patients even when dapagliflozin is held, according to the Kidney International guidelines 43
• The Kidney International guidelines warn that euglycemic diabetic ketoacidosis can occur even with normal blood glucose levels when taking dapagliflozin 43

Common Pitfalls to Avoid

• The Kidney International guidelines advise against discontinuing dapagliflozin solely because eGFR falls below 45 mL/min/1.73 m², as cardiovascular and renal protective benefits persist even when glycemic efficacy is lost 42, 43
• Patients should be counseled about genital mycotic infections, which occur in approximately 6% of patients on SGLT2 inhibitors versus 1% on placebo, according to the Kidney International guidelines 43

Initiating Dapagliflozin in Patients with Existing Sitagliptin/Metformin Regimen

Patient Selection and Dosing

• The American College of Cardiology recommends starting dapagliflozin 10 mg once daily for cardiovascular or renal protection in patients with ASCVD, heart failure, or CKD with eGFR ≥25 mL/min/1.73 m², without requiring titration 44, 45
• For patients with eGFR ≥45 mL/min/1.73 m², the Kidney International guidelines suggest starting dapagliflozin 5 mg once daily for additional glycemic control, with the option to increase to 10 mg once daily if needed 44

Renal Function Assessment and Medication Adjustments

• The Kidney International guidelines recommend checking eGFR before starting dapagliflozin and continuing metformin 500 mg BID without adjustment if eGFR ≥60 mL/min/1.73 m² 46
• For patients with eGFR 45-59 mL/min/1.73 m², consider reducing metformin to half the maximum dose, and if eGFR 30-44 mL/min/1.73 m², reduce metformin to maximum 1000 mg/day 46, 44
• The Kidney International guidelines also suggest continuing sitagliptin 50 mg BID without adjustment if eGFR ≥45 mL/min/1.73 m², and reducing sitagliptin to 50 mg once daily if eGFR 30-44 mL/min/1.73 m² 44

Safety and Monitoring

• The Kidney International guidelines state that the combination of metformin, sitagliptin, and dapagliflozin has low hypoglycemia risk, and no preemptive dose reduction is needed when adding dapagliflozin to this regimen 46
• Genital mycotic infections occur in approximately 6% of patients on SGLT2 inhibitors, and daily hygienic measures may reduce this risk 44
• Recheck eGFR within 1-2 weeks, then at least every 3-6 months if eGFR 45-59 mL/min/1.73 m², or annually if eGFR ≥60 mL/min/1.73 m² 46

Dapagliflozin Dosing in Heart Failure

Standard Dosing Across All Heart Failure Types

• Dapagliflozin 10 mg once daily is the universal dose for heart failure, whether the patient has reduced ejection fraction (≤40%), mildly reduced ejection fraction (41-49%), or preserved ejection fraction (≥50%), and the dose is identical for patients with type 2 diabetes, prediabetes, or normoglycemia 47

Clinical Evidence Supporting 10mg Dosing

• The DAPA-HF trial demonstrated that 10 mg daily reduced the primary outcome of cardiovascular death or worsening heart failure by 26% (HR 0.74, 95% CI 0.65-0.85) over 18.2 months in patients with heart failure with reduced ejection fraction (HFrEF) 47
• The DELIVER trial showed that 10 mg daily reduced worsening heart failure or cardiovascular death by 18% (HR 0.82, 95% CI 0.73-0.92) in patients with heart failure with preserved ejection fraction (HFpEF) 47

Ceiling Doses for Dapagliflozin and Sitagliptin

Standard Dosing Regimens

• The maximum approved daily dose is 10 mg for dapagliflozin and 100 mg for sitagliptin, and these doses can be safely combined without requiring adjustment of either medication 48, 49
• 10 mg once daily is the ceiling dose for all indications including glycemic control, heart failure, and chronic kidney disease 48, 49
• 100 mg once daily is the ceiling dose for all patients with normal renal function 48, 49
• No dose titration is required or recommended above 100 mg daily 48, 49

Dapagliflozin and Linagliptin Dosing in Stage 3b CKD

Introduction to Dosing

• The American College of Cardiology recommends a maximum dose of dapagliflozin of 10 mg once daily and linagliptin of 5 mg once daily for patients with stage 3b CKD (eGFR 30-44 mL/min/1.73 m²) and diabetes, with no dose adjustment required for either medication at this level of renal function 50

Dapagliflozin Dosing

• For patients with stage 3b CKD, the standard dose of dapagliflozin remains 10 mg once daily, regardless of whether the indication is glycemic control, cardiovascular protection, or renal protection, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guideline 50
• At eGFR 30-44 mL/min/1.73 m², dapagliflozin 10 mg daily is the recommended dose and no reduction is required, according to the National Kidney Foundation 50

Linagliptin Dosing

• Linagliptin requires no dose adjustment regardless of renal function, with the standard dose remaining 5 mg once daily even in severe renal impairment, as stated by the American Diabetes Association 50
• Linagliptin is the only DPP-4 inhibitor that does not require dose adjustment at any level of renal impairment, including stage 3b CKD, as recommended by the European Association for the Study of Diabetes 50

Safety Considerations

• The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends assessing volume status before initiation of dapagliflozin and considering reducing concurrent diuretic doses to prevent excessive volume depletion 50
• The American College of Cardiology recommends maintaining at least low-dose insulin in insulin-requiring patients even when dapagliflozin is held during illness 50
• The National Kidney Foundation recommends monitoring for genital mycotic infections, which occur in approximately 6% of patients on SGLT2 inhibitors 50

Dapagliflozin Use in Patients with Urinary Tract Infections

Risk of Euglycemic Diabetic Ketoacidosis

• Euglycemic diabetic ketoacidosis can occur even with normal blood glucose levels when taking dapagliflozin, and may present with nonspecific symptoms like malaise, nausea, vomiting, or abdominal pain, according to the Mayo Clinic Proceedings 51
• Factors that trigger DKA include intercurrent illness, such as UTI, reduced food and fluid intake, reduced insulin doses, and the continued use of SGLT2 inhibitors during illness, as reported in the Mayo Clinic Proceedings 51

Volume Depletion Risk

• SGLT2 inhibitors cause clinically significant volume depletion, for which older adults and those with concurrent diuretic therapy are at greater risk, as noted in the Mayo Clinic Proceedings 51 and Diabetes Care 52

Clinical Algorithm for Holding Dapagliflozin

• UTI requiring hospitalization is a condition where dapagliflozin should be held, as recommended in the Mayo Clinic Proceedings 51
• UTI in patients with recurrent or severe urinary tract infections is another condition where dapagliflozin should be held, according to Diabetes Care 52

Management of Urinary Urgency in Patients Taking Dapagliflozin for Cardiovascular/Renal Protection

Introduction to Dapagliflozin Therapy

• The American Diabetes Association recommends that patients on dapagliflozin for cardiovascular/renal protection should continue with the standard 10 mg daily dose to maintain therapeutic benefit, despite potential urgency symptoms, as it provides a 26% reduction in cardiovascular death or heart failure hospitalization and a 39% reduction in kidney disease progression 53

Management Considerations

• For patients with moderate urgency symptoms on dapagliflozin for cardiovascular/renal protection, symptomatic management with behavioral modifications should be attempted first, considering the significant mortality benefit of the medication 53
• The standard dose of 10 mg daily should not be reduced for heart failure or CKD indications, as all cardiovascular and renal outcome trials used this fixed dose, according to the American Heart Association guidelines 53

Dapagliflozin for Renal and Cardiovascular Protection

Evidence Supporting Initiation

• The European Society of Cardiology recommends treatment with an SGLT2 inhibitor (empagliflozin, canagliflozin, or dapagliflozin) for patients with eGFR 30 to <90 mL/min/1.73 m², as it is associated with a lower risk of renal endpoints 54
• The American College of Cardiology and European Society of Cardiology-aligned guidelines suggest that dapagliflozin can be initiated at 10 mg daily when eGFR ≥25 mL/min/1.73 m² for cardiovascular and renal protection, with benefits independent of diabetes status, although the exact guideline society is not specified in this context 54

Dosing and Administration

• The recommended dose is 10 mg orally once daily for cardiovascular and renal protection, regardless of diabetes status, with no dose adjustment or up-titration required, as dapagliflozin does not affect blood pressure, heart rate, or potassium levels significantly 55, 56

Cardiovascular and Renal Protection with Dapagliflozin

Guideline Recommendations

• The American Diabetes Association recommends SGLT2 inhibitors, such as dapagliflozin, for cardiovascular and renal protection, irrespective of the need for additional glucose lowering, and irrespective of metformin use 57
• The multispecialty consensus recommends SGLT2 inhibitors primarily for cardiovascular and renal protection, not for glucose lowering 58

Clinical Benefits

• Dapagliflozin reduces cardiovascular death or heart failure hospitalization, although the exact percentage is not specified in the cited references 58, 57
• GLP-1 receptor agonists may be considered for additional glucose lowering in patients with eGFR <45 mL/min/1.73 m², as recommended by the multispecialty consensus 58

Replacement of Gliclazide with Dapagliflozin in Type 2 Diabetes Management

Introduction to Dapagliflozin Benefits

• The American College of Cardiology recommends replacing gliclazide with dapagliflozin for patients with type 2 diabetes on metformin, as dapagliflozin provides superior cardiovascular and renal protection, reduces mortality, and improves glycemic variability without causing hypoglycemia—benefits that gliclazide does not offer 59, 60, 61
• SGLT2 inhibitors like dapagliflozin are recommended as priority agents for patients with type 2 diabetes, independent of baseline HbA1c or need for additional glucose lowering, according to the American College of Cardiology and Kidney International 59, 60, 61

Cardiovascular and Renal Protection

• The 2020 American College of Cardiology consensus and 2024 European Society of Cardiology guidelines give Class I, Level A recommendations for SGLT2 inhibitors in patients with diabetes and established cardiovascular disease, heart failure, or chronic kidney disease 59, 61
• Dapagliflozin reduces the risk of cardiovascular death or heart failure hospitalization by 26-29%, and reduces kidney disease progression by 39-44%—benefits that sulfonylureas like gliclazide do not provide 60

Practical Implementation

• Check eGFR: Dapagliflozin can be initiated if eGFR ≥25 mL/min/1.73 m² for cardiovascular/renal protection, or ≥45 mL/min/1.73 m² if the primary goal is glycemic control, as recommended by Kidney International 60
• Exclude contraindications: Pregnancy, breastfeeding, or dialysis, according to the American College of Cardiology 59
• Stop gliclazide completely when starting dapagliflozin, as the combination increases hypoglycemia risk without additional cardiovascular benefit, as stated by the American College of Cardiology and Kidney International 59, 60
• Start dapagliflozin 10 mg once daily—this is the fixed dose for all indications (cardiovascular, renal, and glycemic control), with no titration required, according to the American College of Cardiology 59

Special Considerations

• If eGFR is 25-44 mL/min/1.73 m², dapagliflozin 10 mg daily is still appropriate for cardiovascular and renal protection, but glucose-lowering efficacy will be reduced, as recommended by Kidney International 60
• If eGFR is <25 mL/min/1.73 m², do not initiate dapagliflozin, but if already on treatment, it may be continued until dialysis is required, according to Kidney International 60
• Metformin should be stopped if eGFR falls below 30 mL/min/1.73 m², but dapagliflozin can be continued for cardiovascular and renal protection, as recommended by Kidney International 60

Age Limits and Safety Considerations for SGLT2 Inhibitors

General Safety Profile and Age-Related Risks

• Elderly patients, particularly those ≥75 years, face increased risks of hypotension, which requires heightened vigilance but does not contraindicate the use of SGLT2 inhibitors, according to the European Heart Journal 62
• The European Heart Journal recommends assessing volume status before initiation of SGLT2 inhibitors in all elderly patients, especially those ≥75 years or on loop diuretics, to prevent excessive volume depletion 62, 63

Renal Function and Cardiovascular Protection

• The American College of Cardiology recommends that both Jardiance and Farxiga can be initiated if eGFR ≥25 mL/min/1.73 m² for heart failure or chronic kidney disease indications, regardless of age, with a strength of evidence based on studies such as those published in the Journal of the American College of Cardiology 64

Critical Safety Precautions

• The European Heart Journal suggests considering reducing concurrent diuretic doses when starting SGLT2 inhibitors to prevent excessive volume depletion, and monitoring for potential interactions with other medications that increase volume depletion risk, such as NSAIDs and high-dose diuretics 62, 63

Cardiorenal Protection with Dapagliflozin

Primary Evidence for Early Cardiorenal Protection

• The American Diabetes Association recommends dapagliflozin 10 mg once daily for patients with type 2 diabetes at high cardiovascular or renal risk (eGFR ≥25 mL/min/1.73 m² and UACR ≥200 mg/g) to provide robust cardiorenal protection, independent of glycemic control needs 65, 66
• Dapagliflozin reduces the primary composite outcome (≥50% sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death) by 39% (HR 0.61, 95% CI 0.51-0.72, P<0.001) in patients with chronic kidney disease and albuminuria, as demonstrated in the DAPA-CKD trial 65
• Renal-specific benefits of dapagliflozin include a 44% reduction in kidney-specific composite outcome (sustained eGFR decline ≥50%, end-stage kidney disease, or renal death; HR 0.56, 95% CI 0.45-0.68, P<0.001) 65
• Dapagliflozin slows the decline of eGFR over time and reduces the progression to end-stage renal disease 65
• Cardiovascular benefits of dapagliflozin include a 29% reduction in cardiovascular death or heart failure hospitalization (HR 0.71, 95% CI 0.55-0.92, P=0.009) and a 31% reduction in all-cause mortality (HR 0.69, 95% CI 0.53-0.88, P<0.004) 65

Clinical Decision Algorithm for Initiation

• The American Diabetes Association guidelines suggest checking eGFR (must be ≥25 mL/min/1.73 m² for cardiovascular/renal protection) and assessing albuminuria (UACR ≥200 mg/g provides strongest evidence for benefit) before initiating dapagliflozin 65, 66
• Dapagliflozin 10 mg once daily should be initiated early, as part of foundational therapy alongside ACE inhibitors/ARBs, without waiting for "optimal" glycemic control, as benefits are independent of baseline HbA1c 66

Key Advantages of Early Initiation

• The 2024 American Diabetes Association guidelines emphasize that SGLT2 inhibitors, such as dapagliflozin, should be initiated in patients with type 2 diabetes and increased cardiovascular risk or established cardiovascular disease to prevent the development of incident heart failure 66
• Dapagliflozin reduces heart failure hospitalization by 17% (HR 0.83, 95% CI 0.73-0.95) in patients without prior heart failure, demonstrating clear benefit in primary prevention 66

Integration with Other Cardiovascular Medications

• The American Diabetes Association guidelines provide an A-level recommendation for SGLT2 inhibitor use, such as dapagliflozin, in patients with type 2 diabetes and diabetic kidney disease with eGFR ≥20 mL/min/1.73 m² and UACR ≥200 mg/g to reduce chronic kidney disease progression and cardiovascular events 65

Dapagliflozin Use in Patients with eGFR 43.18 ml/min

Introduction to Dapagliflozin

• The American Diabetes Association recommends SGLT2 inhibitors, such as dapagliflozin, for patients with diabetic kidney disease when eGFR is >20 mL/min/1.73 m², with a standard dose of 10 mg once daily for cardiovascular and renal protection, regardless of the indication being type 2 diabetes or heart failure 67

Evidence-Based Rationale

• The American Diabetes Association guidelines support the use of dapagliflozin at an eGFR of 43.18 ml/min, based on Level A evidence, representing a change from previous thresholds of >25 mL/min/1.73 m² 67
• The American College of Cardiology provides Class I, Level A recommendations for SGLT2 inhibitors in patients with diabetes and chronic kidney disease, including the use of dapagliflozin for cardiovascular and renal protection 68

Dosing and Administration

• The American Diabetes Association and the American College of Cardiology recommend continuing dapagliflozin therapy even if eGFR subsequently falls below 25 mL/min/1.73 m² until dialysis is initiated, with no dose adjustment needed at eGFR 43.18 ml/min for cardiovascular/renal indications 67

Safety Precautions

• The American College of Cardiology advises against withholding ACE inhibitors/ARBs when starting dapagliflozin, but recommends using clinical judgment if simultaneously initiating or up-titrating these agents in patients with impaired renal function 68

Jardiance and Renal Protection

Initiation and Continuation Guidelines

• The American Diabetes Association recommends initiating Jardiance at 10 mg once daily if eGFR ≥20 mL/min/1.73 m² for cardiovascular and renal protection, regardless of diabetes status 69
• The American Diabetes Association updated its guidelines in 2025 to support initiation of Jardiance down to eGFR 20 mL/min/1.73 m² for cardiovascular and renal protection 69

Management of Acute Illness

• The Lancet Diabetes and Endocrinology recommends withholding Jardiance during acute illness with reduced oral intake, fever, vomiting, or diarrhea to prevent volume depletion and euglycemic diabetic ketoacidosis 70, 71
• Patients should be monitored for diabetic ketoacidosis even with normal blood glucose levels, as euglycemic DKA can occur 70, 71

Common Pitfalls to Avoid

• The American Diabetes Association advises against discontinuing Jardiance when eGFR falls below 45 mL/min/1.73 m², as cardiovascular and renal benefits persist at lower eGFR levels 69

Dapagliflozin for Cardiovascular and Renal Protection in Patients with CKD and Diabetes

Patient Eligibility and Initiation

• Initiate dapagliflozin 10 mg once daily in adults with type 2 diabetes and chronic kidney disease when estimated glomerular filtration rate (eGFR) is ≥ 25 mL/min/1.73 m² to obtain cardiovascular and renal protection, independent of glycemic control needs or baseline HbA1c. 72
• For patients with eGFR 25–44 mL/min/1.73 m², start dapagliflozin solely for cardiorenal protection (glucose‑lowering effect is minimal but cardiovascular/renal benefits are retained). 72
• Prior to initiation, correct any volume depletion and consider reducing concurrent diuretic doses in individuals at high risk for further volume loss. 72
• High‑priority clinical features that favor initiation:
  
  • Albuminuria with urine albumin‑to‑creatinine ratio (UACR) ≥ 200 mg/g. 72
  • Established atherosclerotic cardiovascular disease or heart failure. 73

Dosing and Medication Adjustments

• Standard dose: 10 mg orally once daily for all approved indications; no titration is required for cardiovascular or renal protection. 72
• When dapagliflozin is added to insulin or sulfonylurea therapy, reduce the doses of those agents to mitigate hypoglycemia risk and monitor glucose closely for the first 2–4 weeks. 72
• In patients receiving loop or thiazide diuretics, consider a modest diuretic dose reduction at initiation to avoid excessive volume depletion. 72
• Continue ACE inhibitors or ARBs without dose adjustment when dapagliflozin is started. 72

Monitoring and Expected eGFR Changes

• An acute, reversible eGFR decline of ~2–5 mL/min/1.73 m² may occur within the first 2–4 weeks; this hemodynamic dip should not prompt discontinuation of dapagliflozin. 72

Evidence‑Based Clinical Benefits

• Dapagliflozin produces a 44 % relative reduction in a kidney‑specific composite outcome (sustained eGFR decline ≥ 50 %, end‑stage kidney disease, or renal death). 73
• It yields a 39 % relative reduction in the primary composite outcome of sustained eGFR decline, end‑stage kidney disease, or cardiovascular/renal death. 73
• Cardiovascular benefit includes a 29 % relative reduction in cardiovascular death or hospitalization for heart failure. 73

Safety Precautions and Patient Education

• Temporarily withhold dapagliflozin during acute illnesses with reduced oral intake, fever, vomiting, or diarrhea, and stop at least 3 days before major surgery or procedures requiring prolonged fasting. 72
• Counsel patients that genital mycotic infections occur in approximately 6 % of treated individuals versus 1 % with placebo; emphasize daily hygiene. 72
• Warn about the risk of euglycemic diabetic ketoacidosis and advise immediate medical evaluation for malaise, nausea, vomiting, or abdominal pain even when blood glucose is normal. 72
• If dapagliflozin must be held temporarily, maintain a low‑dose insulin regimen in insulin‑requiring patients to prevent hyperglycemia. 72

Common Pitfalls to Avoid

• Do not discontinue dapagliflozin when eGFR falls below 45 mL/min/1.73 m²; cardiovascular and renal benefits persist. 72
• Do not stop the drug because of the expected initial eGFR dip in the first 2–4 weeks. 72
• Do not reduce the dose below 10 mg for cardiovascular or renal indications, even if glycemic efficacy wanes at lower eGFR. 72

Integration with Other CKD Therapies

• Dapagliflozin should be used alongside ACE inhibitors or ARBs (continued unchanged) as part of first‑line CKD management. 72
• When combined with mineralocorticoid receptor antagonists (e.g., finerenone), dapagliflozin provides additive renal benefits and may lessen hyperkalemia risk. 72
• SGLT2 inhibition is positioned as foundational therapy for slowing CKD progression and preventing cardiovascular events, irrespective of glycemic status. 72

Combined Use of Dapagliflozin and Semaglutide in Chronic Kidney Disease

Indications and Initiation Criteria

• Dapagliflozin should be started in adults with CKD when estimated glomerular filtration rate (eGFR) is ≥ 20 mL/min/1.73 m² and urine albumin‑to‑creatinine ratio (UACR) is ≥ 200 mg/g; it serves as a foundational therapy for renal protection. 74

• Semaglutide can be added to dapagliflozin for additional cardiovascular and glycemic benefits; it is approved for use across all stages of CKD without dose adjustment. 75

Efficacy Outcomes (Evidence from Randomized Trials)

• In the DAPA‑CKD trial, dapagliflozin 10 mg daily reduced the composite of sustained ≥ 50 % eGFR decline, end‑stage kidney disease, or renal death by 44 % (hazard ratio 0.56; 95 % CI 0.45–0.68). This high‑quality RCT provides strong evidence for renal benefit. 74

• The same trial showed a 29 % reduction in the composite of cardiovascular death or hospitalization for heart failure (HR 0.71; 95 % CI 0.55–0.92), indicating robust cardiovascular protection. 74

• All‑cause mortality was lowered by 31 % with dapagliflozin (HR 0.69; 95 % CI 0.53–0.88), further supporting its mortality benefit. 74

• Benefits of dapagliflozin were consistent regardless of diabetes status; 67.5 % of participants had type 2 diabetes and 32.5 % did not, with similar effect sizes in both subgroups. 74

• Cardiovascular outcome trials of semaglutide demonstrated a 36 % relative risk reduction in new or worsening nephropathy (composite of persistent UACR > 300 mg/g, doubling of serum creatinine, or end‑stage renal disease). Although the dedicated renal outcome trial (FLOW) is ongoing, existing data provide moderate‑to‑strong evidence for renal benefit. [76][74]

Guideline Recommendations

• The 2023 American Diabetes Association (ADA) Standards of Care explicitly recommend SGLT2 inhibitors (e.g., dapagliflozin) for slowing CKD progression and reducing cardiovascular events, and GLP‑1 receptor agonists (e.g., semaglutide) for complementary cardiovascular protection and additional glycemic control when needed. 74

Mechanisms of Action

• Dapagliflozin lowers intraglomerular pressure, attenuates eGFR decline, and reduces albuminuria by inhibiting tubular glucose reabsorption, thereby providing renal hemodynamic protection. 76

• Semaglutide exerts cardiovascular and renal benefits through GLP‑1 receptor activation, leading to improved endothelial function, weight loss, and enhanced glycemic control. 74

Integration with Existing CKD Therapies

• Continuation of ACE inhibitors or ARBs is safe when dapagliflozin is added; > 99 % of DAPA‑CKD participants were on renin‑angiotensin‑aldosterone system blockers, and the combination showed additive renal protection without dose adjustments. 74

• Dapagliflozin should not be discontinued when eGFR falls below 45 mL/min/1.73 m², as cardiovascular and renal protective effects persist even though glucose‑lowering efficacy diminishes. This recommendation is based on trial data demonstrating ongoing benefit at lower eGFR levels. 77

Cardiovascular and Renal Benefits of Dapagliflozin in Patients with eGFR ≥ 20 mL/min/1.73 m²

Efficacy Outcomes

• In the DAPA‑CKD randomized trial, patients with baseline eGFR as low as 25 mL/min/1.73 m² experienced a 39 % relative reduction in the composite of sustained eGFR decline, end‑stage kidney disease, or cardiovascular/renal death (hazard ratio 0.61, 95 % CI 0.51–0.72)【78】.
• The same trial demonstrated that dapagliflozin reduced cardiovascular death or heart‑failure hospitalization by 29 % (HR 0.71, 95 % CI 0.55–0.92) and all‑cause mortality by 31 % (HR 0.69, 95 % CI 0.53–0.88)【78】.
• The EMPA‑KIDNEY trial (a sister SGLT2‑inhibitor study) enrolled participants with eGFR down to 20 mL/min/1.73 m² and reported consistent cardiovascular and renal benefits, confirming the safety and efficacy of this drug class at very low eGFR levels【78】.

Renal Function Trajectory

• Initiation of dapagliflozin is typically followed by an acute, reversible eGFR dip of 2–5 mL/min/1.73 m² within the first 2–4 weeks, reflecting hemodynamic changes rather than tubular injury【78】.
• After the initial dip, eGFR stabilizes and the long‑term decline is slower compared with placebo, indicating a net renoprotective effect【78】.

Combination with Renin‑Angiotensin System Blockade

• More than 99 % of DAPA‑CKD participants were receiving ACE inhibitors or ARBs, and the combination with dapagliflozin provided additive renal protection without requiring dose adjustments of the renin‑angiotensin agents【78】.

Cardiovascular Safety Across Age Groups

• Subgroup analysis showed that dapagliflozin did not increase cardiovascular risk in patients aged ≥ 75 years (HR 0.95, 95 % CI 0.35–2.62)【78】.

Continuation Thresholds

• Evidence supports continuing dapagliflozin even when eGFR falls below 25 mL/min/1.73 m², as cardiovascular and renal benefits persist until the patient reaches dialysis dependence【78】.

• The drug’s cardiovascular protection remains robust in individuals with recent acute pulmonary congestion, underscoring its utility in high‑risk heart‑failure populations【78】.

Approved Therapeutic Indications of Dapagliflozin

Regulatory Approval

• Dapagliflozin, an SGLT2‑inhibitor, is approved for the treatment of adults with type 2 diabetes mellitus, chronic heart failure, and chronic kidney disease, reflecting its cardiovascular and renal protective benefits 79

Discontinue Glipizide and Initiate Dapagliflozin for Type 2 Diabetes with CKD

Rationale for Switching Therapy

• Glipizide provides no cardiovascular or renal protection and increases hypoglycemia risk, especially in CKD stage 3b patients; therefore it should be stopped when starting dapagliflozin – KDIGO 2020 guideline emphasizes the lack of cardiorenal benefit with sulfonylureas. 80
• KDIGO 2020 guidelines give a strong (Grade A) recommendation that SGLT2 inhibitors be used as first‑line therapy (alongside metformin) in adults with type 2 diabetes and chronic kidney disease, relegating sulfonylureas to “other options” only when preferred agents cannot be used. 80

Dapagliflozin Dosing and Indications at eGFR 44 mL/min/1.73 m²

• Initiate dapagliflozin 10 mg once daily for cardiorenal protection; this dose is evidence‑based for patients with eGFR ≥ 25 mL/min/1.73 m². 80
• Although dapagliflozin’s glucose‑lowering effect is markedly reduced when eGFR < 45 mL/min/1.73 m², the 10 mg dose remains appropriate for reducing kidney‑failure progression, cardiovascular death, and heart‑failure hospitalization. 80

Pre‑Initiation Assessment

• Confirm that eGFR is ≥ 25 mL/min/1.73 m² (the patient’s eGFR 44 mL/min/1.73 m² meets this criterion) before starting dapagliflozin. 80
• Evaluate volume status and correct any depletion; consider temporary reduction of concurrent loop or thiazide diuretics. [80][81]

Medication Adjustments

• Stop glipizide 5 mg twice daily completely at the time dapagliflozin is started; tapering is unnecessary because the combination adds hypoglycemia risk without cardiovascular benefit. 81
• If the patient is on metformin and eGFR is 30–44 mL/min/1.73 m², continue metformin but limit the dose to ≤ 1000 mg per day. 80
• Start dapagliflozin 10 mg once daily; no titration is required for any cardiorenal indication. 81

Monitoring After Initiation

• Re‑measure eGFR 1–2 weeks after starting dapagliflozin; a modest, reversible dip of 2–5 mL/min/1.73 m² is expected and should not trigger discontinuation. 81
• Closely monitor blood glucose for the first 2–4 weeks, especially if insulin or other glucose‑lowering agents are still being used. 81
• Re‑assess volume status at follow‑up, with particular attention to elderly patients or those on diuretics. 81

Patient Education

• Inform patients that genital mycotic infections occur in roughly 6 % of dapagliflozin users versus 1 % with placebo; advise daily hygiene to reduce risk. 81
• Warn about the possibility of euglycemic diabetic ketoacidosis and instruct patients to seek immediate care for unexplained malaise, nausea, vomiting, or abdominal pain even when blood glucose is normal. 81
• Advise patients to withhold dapagliflozin during acute illnesses with reduced oral intake, fever, vomiting, or diarrhea, and to stop the drug at least 3 days before major surgery or any procedure requiring prolonged fasting. 81

Common Pitfalls to Avoid

• Do not discontinue dapagliflozin solely because eGFR falls below 45 mL/min/1.73 m²; cardiorenal benefits persist despite loss of glycemic efficacy. 81
• Do not stop dapagliflozin in response to the expected early eGFR dip; the change is hemodynamic and reversible, not indicative of kidney injury. 81
• Do not reduce the dapagliflozin dose below 10 mg for cardiovascular or renal indications, even at lower eGFR levels; all outcome trials used the fixed 10 mg dose. 81
• Do not combine dapagliflozin with glipizide, as the combination raises hypoglycemia risk without adding cardiovascular benefit. 81

Additional Glycemic Management Options (if needed after stopping glipizide)

• Consider a GLP‑1 receptor agonist (e.g., liraglutide, dulaglutide, semaglutide) for patients with eGFR > 30 mL/min/1.73 m²; these agents provide additional cardiovascular protection and require no dose adjustment. [80][81]
• Insulin remains fully effective regardless of renal function and can be used as the primary glucose‑lowering agent when aggressive glycemic control is required. 80
• DPP‑4 inhibitors such as linagliptin can be used without dose adjustment at any eGFR level, though they lack the robust cardiorenal benefits of SGLT2 inhibitors and GLP‑1 receptor agonists. 80

Dapagliflozin for Cardiorenal Protection in Chronic Kidney Disease

Efficacy Outcomes

• Dapagliflozin reduces the composite of sustained eGFR decline ≥ 50 %, end‑stage kidney disease, or renal/cardiovascular death by 39 % (hazard ratio 0.61, 95 % CI 0.51–0.72) in patients with CKD and albuminuria. 82
• Kidney‑specific outcomes (sustained eGFR decline, end‑stage renal disease, or renal death) improve by 44 % (hazard ratio 0.56, 95 % CI 0.45–0.68). 82
• Cardiovascular death or hospitalization for heart failure decreases by 29 % (hazard ratio 0.71, 95 % CI 0.55–0.92). 82
• All‑cause mortality is reduced by 31 % (hazard ratio 0.69, 95 % CI 0.53–0.88). 82

Comparison with Sulfonylureas

• Sulfonylureas (e.g., glipizide) provide no cardiovascular or renal protection and increase the risk of hypoglycemia, especially in CKD stage 3b patients. 82
• Combining dapagliflozin with a sulfonylurea raises hypoglycemia risk without adding cardiovascular benefit; therefore, co‑administration should be avoided. 82

Eligibility & Pre‑Initiation Assessment

• Dapagliflozin may be started when eGFR ≥ 25 mL/min/1.73 m²; patients with eGFR 44 mL/min/1.73 m² meet this criterion. 82
• Prior to initiation, evaluate volume status and correct any depletion; temporary reduction of concurrent loop or thiazide diuretics may be needed. 83

Dosing for Cardiorenal Indication

• The evidence‑based dose for renal or cardiovascular protection is dapagliflozin 10 mg once daily, appropriate for eGFR ≥ 25 mL/min/1.73 m². No dose titration is required. 82

Concomitant Medication Adjustments

• Discontinue sulfonylureas (e.g., glipizide 5 mg twice daily) at the time dapagliflozin is started; tapering is unnecessary. 82
• If the patient is on metformin and eGFR is 30–44 mL/min/1.73 m², continue metformin but limit the dose to ≤ 1000 mg per day. 82

Monitoring After Initiation

• Re‑measure eGFR 1–2 weeks after starting dapagliflozin; a modest, reversible dip of 2–5 mL/min/1.73 m² is expected and should not trigger discontinuation. 82
• Monitor blood glucose closely for the first 2–4 weeks, especially if other glucose‑lowering agents remain in use. 83
• Re‑assess volume status at follow‑up, with particular attention to elderly patients or those on diuretics. 83

Safety Education

• Genital mycotic infections occur in ≈ 6 % of dapagliflozin users versus 1 % with placebo; advise daily hygiene to reduce risk. 83
• Warn patients about euglycemic diabetic ketoacidosis and instruct them to seek immediate care for unexplained malaise, nausea, vomiting, or abdominal pain even when blood glucose is normal. 83
• Sick‑day rules: hold dapagliflozin during acute illness with reduced oral intake, fever, vomiting, or diarrhea, and stop the drug at least 3 days before major surgery or any procedure requiring prolonged fasting. 83

Common Pitfalls to Avoid

• Do not discontinue dapagliflozin solely because eGFR falls below 45 mL/min/1.73 m²; cardiorenal benefits persist despite loss of glycemic efficacy. 82
• Do not stop dapagliflozin in response to the expected early eGFR dip; the change is hemodynamic and reversible. 82
• Do not reduce the dapagliflozin dose below 10 mg for cardiovascular or renal indications, even at lower eGFR levels; all outcome trials used the fixed 10 mg dose. 82

Alternative Glycemic Strategies (if additional glucose lowering is needed)

• GLP‑1 receptor agonists (e.g., liraglutide, dulaglutide, semaglutide) can be considered for patients with eGFR > 30 mL/min/1.73 m², providing additional cardiovascular protection without dose adjustment. 82
• Insulin remains fully effective regardless of renal function and may be used as the primary glucose‑lowering agent when aggressive glycemic control is required. 82

Cost and Access Considerations

• No generic SGLT2 inhibitors are currently available in the United States; dapagliflozin, empagliflozin, and canagliflozin are all brand‑name products. 82
• Manufacturer‑sponsored patient assistance programs (e.g., AstraZeneca’s AZ&Me Prescription Savings Program) may reduce out‑of‑pocket costs for eligible patients. 82
• Empagliflozin and canagliflozin have similar cardiorenal benefits to dapagliflozin and may be preferred based on formulary coverage. 82

Integration with Established CKD Therapies

• Continue ACE inhibitors or ARBs unchanged when initiating dapagliflozin as part of first‑line CKD management. 82
• SGLT2 inhibition is positioned as foundational therapy for slowing CKD progression and preventing cardiovascular events, irrespective of glycemic status. 82

Acute Kidney Injury Assessment and Dapagliflozin Initiation Criteria

AKI Definition and Diagnostic Thresholds

• An acute kidney injury is defined by either an increase in serum creatinine ≥ 0.3 mg/dL within 48 hours or an increase to ≥ 1.5 times baseline within 7 days【84】【85】.

Interpreting a Recent Creatinine Rise

• A rise in serum creatinine from 0.9 mg/dL to 1.48 mg/dL (≈ 64 % increase) satisfies the AKI definition if the change occurred within a 7‑day window【85】.

Excluding Acute Kidney Injury Before Starting Dapagliflozin

• To rule out AKI, clinicians should review the timing of the creatinine increase and systematically exclude:
  • Prerenal causes (e.g., volume depletion, hypotension)
  • Intrinsic causes (e.g., nephrotoxic drugs, contrast exposure, NSAIDs)
  • Post‑renal obstruction【84】【85】.

Medication Review for Nephrotoxic Agents

• Prior to dapagliflozin initiation, the medication list must be examined for recent exposure to nephrotoxic agents such as NSAIDs or iodinated contrast, and these agents should be avoided or discontinued if possible【84】【85】.

Management of Renin‑Angiotensin System Inhibitors

• Angiotensin‑converting‑enzyme inhibitors or angiotensin‑II receptor blockers can be continued when dapagliflozin is started unless the creatinine rises > 30 % during the initiation or dose titration of the RAS inhibitor【86】.

Inpatient Initiation of Dapagliflozin – Evidence‑Based Recommendations

Eligibility Criteria for Initiation

• Hospitalized adults with type 2 diabetes, heart failure, or chronic kidney disease can safely start dapagliflozin when they are hemodynamically stable, euvolemic, and have an estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m², provided there is no acute illness that predisposes to ketoacidosis (American College of Cardiology) 87.

• Patients must have no exposure to IV vasodilators, inotropes, or escalating IV loop diuretics in the 24 hours preceding initiation (American College of Cardiology) 88.

Safety and Tolerability

• SGLT2 inhibitors, including dapagliflozin, show a robust safety profile in the inpatient setting, with minimal impact on blood pressure and no excess risk of symptomatic hypotension even when systolic BP is as low as 95 mmHg (American College of Cardiology) 87.

• Acute kidney injury (AKI) rates are not increased by initiating dapagliflozin during hospitalization, even among patients who have reduced baseline kidney function (American College of Cardiology) 87.

• Serious adverse events leading to drug discontinuation were numerically fewer with dapagliflozin compared with placebo in clinical trials (American College of Cardiology) 87.

Clinical Trial Evidence Supporting In‑Hospital Initiation

Medication Management After Initiation

• Reduce insulin dose by ~20 % when baseline HbA1c is < 8.5 % to lower hypoglycemia risk (American College of Cardiology) 87.

• Discontinue sulfonylureas when baseline HbA1c is < 8.5 % (American College of Cardiology) 87.

• Consider lowering concurrent loop diuretic doses, especially in elderly patients, to avoid excessive volume depletion (American College of Cardiology) 87.

• Continue ACE inhibitors or ARBs unchanged; there is no need to withhold these agents when dapagliflozin is started (American College of Cardiology) 87.

Expected Benefits and Outcomes

• If dapagliflozin is not started during hospitalization, there is > 75 % likelihood that the patient will never receive the therapy within the following year, highlighting the inpatient encounter as a critical opportunity (American College of Cardiology) 87.

• Randomized trials confirm that in‑hospital initiation improves post‑discharge dapagliflozin use without increasing medication discontinuation rates (American College of Cardiology) 87.

• Higher absolute risk reductions are anticipated when therapy is started after hospitalization for heart failure or acute kidney injury, owing to the elevated short‑term event rates in these populations (American College of Cardiology) 87.

Contraindications and Pitfalls to Avoid

• Do not withhold dapagliflozin in patients whose eGFR falls below 45 mL/min/1.73 m²; cardiovascular and renal benefits persist despite reduced glucose‑lowering efficacy (American College of Cardiology) 87.

• Do not discontinue dapagliflozin solely because of the expected early eGFR dip (2–5 mL/min/1.73 m²) observed in the first 2–4 weeks; this change is hemodynamic and reversible (American College of Cardiology) – Note: evidence for this statement is embedded in the overall safety data cited above 87.

• Prioritize dapagliflozin initiation over dose escalation of other guideline‑directed medical therapies; its benefits are additive and should not be delayed (American College of Cardiology) 87.

• Avoid withholding dapagliflozin due to concerns about hypoglycemia or euglycemic diabetic ketoacidosis in patients without prior episodes; trial data show these complications are rare and not increased (American College of Cardiology) 87.

• Hemodynamic instability—requiring IV vasodilators, inotropes, or escalating IV diuretics—remains a contraindication to inpatient initiation (American College of Cardiology) 88.